EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France

Benjamin Wyplosz, Benjamin Grenier iD, Nicolas Roche, François Roubille, Paul Loubet, Ariane Sultan, Bertrand Fougère, Jérôme Fernandes, Didier Duhot, Bruno Moulin, Fanny Raguideau, Emmanuelle Blanc und 1 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0329703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Benjamin Wyplosz und 12 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, Hospitalisation à Domicile, Département Adulte, Institut Pasteur, Centre Médical, Paris, France. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Vaccination Coverage, Pneumococcal Infections, Vaccination. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years).

Methods

We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021.

Results

In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an “age ≥65 years” for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18–65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies.

Conclusion

In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal VaccinesVaccination CoveragePneumococcal InfectionsVaccinationHumansAgedFranceMaleRetrospective StudiesFemaleMiddle AgedAdultAged, 80 and overRisk FactorsInfluenza VaccinesYoung AdultInfluenza, Human

Substanzen

Pneumococcal VaccinesInfluenza Vaccines23-valent pneumococcal capsular polysaccharide vaccine13-valent pneumococcal vaccine

Autor:innen und Institutionen

  • AP-HP, Hospitalisation à Domicile, Département Adulte, Institut Pasteur, Centre Médical, Paris, France.
  • Epidemiology Department, Heva, Lyon, France.
  • AP-HP, Pneumology, Cochin Hospital, Paris, France.
  • PhyMedExp, University Montpellier, CNRS, INSERM, Cardiology, Montpellier University Hospital, Montpellier, France.
  • Virulence Bactérienne et Infections Chroniques, INSERM U1047, University Montpellier, Service des Maladies Infectieuses et Tropicales, CHU Nîmes, Nîmes, France.
  • PhyMedExp, University Montpellier, CNRS, INSERM, Endocrinology-Diabetology-Nutrition Department, University Montpellier, Montpellier, France.

ORCID-Profile: Benjamin Grenier

Förderung

  • Pfizer France

Zitieren

APA

Wyplosz, B., Grenier, B., Roche, N., Roubille, F., Loubet, P., Sultan, A., Fougère, B., Fernandes, J., Duhot, D., Moulin, B., Raguideau, F., Blanc, E., & Goussiaume, G. (2025). Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France. PLOS One. https://doi.org/10.1371/journal.pone.0329703

Vancouver

Wyplosz B, Grenier B, Roche N, Roubille F, Loubet P, Sultan A, et al. Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France. PLOS One. 2025. doi:10.1371/journal.pone.0329703

BibTeX
@article{Wyplosz2025,
  author = {Wyplosz, Benjamin and Grenier, Benjamin and Roche, Nicolas and Roubille, François and Loubet, Paul and Sultan, Ariane and Fougère, Bertrand and Fernandes, Jérôme and Duhot, Didier and Moulin, Bruno and Raguideau, Fanny and Blanc, Emmanuelle and Goussiaume, Gwenael},
  title = {Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0329703}
}
Kostenlos starten →